https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

Promo Image
Lipodystrophy/Body Fat

Protein Accumulation Might Cause Fat Deposits, Other Side Effects in HIV-Positive People Taking Protease Inhibitors, Study Says

Similarities between genetic conditions that cause early aging and side effects experienced by some HIV-positive people when taking protease inhibitors might explain the fat accumulation associated with the drugs, according to a study published Monda...

Promo Image

Generic Drugs Used in the Treatment of HIV Infection

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Generic NameManufacturer NameApproval DateTime to Approvaldidanosine (ddI)Delayed Release capsulesBarr Laboratories, Inc.03-Dec-046 monthsdidanosine (ddI)for oral solution (pediatric powder), 10 mg...

Promo Image
News

NNRTIs: The Next Generation Approaches (Part I)

Part I

Introduction Mechanisms of NNRTI Activity and HIV NNRTI Resistance NNRTI Resistance in NNRTI-Naive and NNRTI-Experienced Individuals NNRTI Mutations: Resistance and Cross-Resistance NRTI Mutations: The Potential Impact on NNRTIs NNR...

Promo Image

NNRTIs: The Next Generation Approaches (Part II)

Case Study: Patient JD

JD is a 46-year-old gay male. He first learned of his HIV status in 1994 after a former partner with whom he had been in a three-year relationship discovered that he was HIV infected.

JD felt well when he was first tested for...

Promo Image

Pipeline Update: Short Notes on New Anti-HIV Drugs in Development

The Phases of Drug Development Integrase Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Entry Inhibitors Protease Inhibitors Other Types of Anti-HIV Drugs

The Pha...

Promo Image
Conference Coverage

Brecanavir Shows Favorable Pharmacokinetics When Combined With Select PIs in Double-Boosted Regimens

Brecanavir (BCV, GW640385) is a new protease inhibitor (PI) in phase 2b clinical development by GlaxoSmithKline (Glaxo). It has shown powerful antiviral activity against both wild-type and highly drug-resistant HIV. One of its main attributes is that...

Promo Image

Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels

Some protease inhibitors (PIs) -- notably atazanavir (ATV, Reyataz) -- have impaired absorption when coadministered with acid-reducing agents. In addition, antacids, H2 blockers and proton pump inhibitors are available over-the-counter and widely use...

Promo Image
News

Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used

For HIV-infected patients with protease inhibitor (PI) resistance, there has been a lot of good news of late with the advent of PIs such as tipranavir (TPV, Aptivus) and TMC114. There also remains continued interest in the use of dual PIs for the tre...

Promo Image

Two NRTIs or Three? Makes No Difference When Taken With Efavirenz, ACTG 5095 Finds

When prescribing the potent antiretroviral efavirenz (EFV, Sustiva, Stocrin) as part of a first-line treatment regimen, there is no discernible difference between completing the regimen with two nucleoside reverse transcriptase inhibitors (NRTIs) or ...

Promo Image

New Protease Inhibitor Brecanavir Shown to Be Safe and Effective in Small Study

A key dilemma for both patients and doctors is when to use new drugs and new drug classes. A thorough understanding of the characteristics of new drugs helps in choosing what to use and what potential combinations would be appropriate, or when to wai...